Peru’s Health Minister, Silvia Pessah, after announcing the first case of price-fixing agreements for the public purchase of medicines in Peru, has now also revealed that three other similar cases have been identified, which have already been notified to the corresponding authority.
Price manipulation was detected in several products, whose prices for the State appear to have risen significantly and without justification. In one example, Pessah details that a surcharge of over 10 times was discovered for a drug when compared with prices in commercial pharmacies.
As a measure, Pessah also announced that the Ministry of Health (MINSA) would stop buying some of the affected medications, launching a new round of contracts to ensure fair prices. Affected medications include gastrointestinal and cardiovascular treatments, and some used in the treatment of Parkinson’s disease. As it is an ongoing investigation, the names of the companies or individuals involved have not been revealed.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI